ABBV Stock Price - AbbVie Inc. Stock Quote (U.S.: NYSE) - MarketWatch

Open $104.19
Day Range 97.60 - 104.50
52 Week Range 63.12 - 125.86
Market Cap $178.42B
Shares Outstanding 1.59B
Public Float 1.59B
Beta 1.13
Rev. per Employee $972.97K
P/E Ratio 30.12
EPS $3.29
Yield 3.87%
Dividend $0.96
Ex-Dividend Date Apr 12, 2018
Short Interest 16.61M 02/28/18
% of Float Shorted 1.04%
Average Volume 6.21M

5 Day	-13.99%
1 Month	-17.64%
3 Month	-0.41%
YTD	1.13%
1 Year	49.05%

MarketWatch
Other Dow Jones

AbbVie stock tumbles 11% on disappointing results for cancer drug acquired in $5.8 billion deal

Mar. 22, 2018 at 11:05 a.m. ET
by Emma Court

Stock market falls 1% on trade fears; Facebook drops again

Mar. 22, 2018 at 10:57 a.m. ET
by Victor Reklaitis

UPDATE: AbbVie shares plummet 11.7% on cancer drug results

AbbVie Inc. shares dropped 11.7% in early trade Thursday after the company said it will not try for accelerated approval of rovalpituzumab tesirine in third-line relapsed/refractory small cell lung cancer based on the drug's results in a phase 2 trial and the "magnitude of effect across multiple parameters." The decision was made after consulting with the Food and Drug Administration,the company said. AbbVie said it does still believe the drug, also called Rova-T, has potential in small cell lung cancer and other cancers expressing the DLL3 protein, and Rova-T continues to be studied in ongoing phase 3 trials for first-line and second-line small cell lung cancer. AbbVie bought Rova-T in a $5.8 billion deal for Stemcentrx in 2016; Rova-T was the company's lead asset. AbbVie shares have surged 14.5% over the last three months but dropped nearly 3% month-to-date. The S&P 500 has surged 1.1% over the last three months and declined 0.1% month-to-date.

Mar. 22, 2018 at 10:04 a.m. ET
by Emma Court

AbbVie shares slide 11.7%

Mar. 22, 2018 at 10:03 a.m. ET
by Ciara Linnane

AbbVie stock down 9.3% in early trade

Mar. 22, 2018 at 9:50 a.m. ET
by Ciara Linnane

AbbVie shares extend losses, now down 6.6% premarket

Mar. 22, 2018 at 8:56 a.m. ET
by Ciara Linnane

AbbVie shares slump 4.7% premarket

Mar. 22, 2018 at 8:48 a.m. ET
by Ciara Linnane

AbbVie says will not seek accelerated approval for lung cancer drug after mid-stage trial

Mar. 22, 2018 at 8:48 a.m. ET
by Ciara Linnane

Multimillion-dollar drug yanked from market connected to dangerous brain inflammation cases in U.S.

Mar. 8, 2018 at 8:59 a.m. ET
by Emma Court

Biogen, AbbVie's Zinbryta, yanked from market, connected to three U.S. cases of brain inflammation

The Food and Drug Administration is reviewing whether a type of brain inflammation called encephalitis connected to Biogen Inc. and AbbVie Inc.'s multiple sclerosis drug Zinbryta was a result of known side effects of the therapy or have another cause, a FDA spokesperson told MarketWatch. Three U.S. cases of encephalitis related to Zinbryta have been reported in the U.S., though most cases have been reported in Europe, FDA spokesperson Sandy Walsh said. Immune-mediated disorders, which can cause encephalitis, are known side effects of Zinbryta and warned about on the product's U.S. label; the FDA is reviewing whether immune-mediated disorders or something else caused the reports of encephalitis, according to Walsh. Biogen and AbbVie said last week that they are voluntarily withdrawing Zinbryta from global markets, a move that followed the European Medicines Agency's investigation into reports of inflammatory encephalitis and meningioencephalitis, also a type of brain inflammation. The voluntary withdrawal decision was not made because of any FDA action, a spokesperson told MarketWatch last week. Zinbryta, which has been connected with serious liver injury, hypersensitivity reactions and inflammatory and immune toxicity, has been known to have a "complex safety profile" since approval, Walsh said, resulting in use mostly in patients who haven't responded well to two or more multiple sclerosis drugs, a warning on the drug's box and restricted distribution of the product. AbbVie shares declined 1.1% in Wednesday trade and Biogen shares slumped 0.6%. AbbVie shares have surged 20% over the last three months, Biogen shares have dropped 11% and shares of the S&P 500 have risen 2.9%.

Mar. 7, 2018 at 12:12 p.m. ET
by Emma Court

FDA is reviewing what caused those encephalitis cases and their causes

Mar. 7, 2018 at 11:33 a.m. ET
by Emma Court

Three cases of encephalitis related to Biogen, AbbVie's Zinbryta have been reported in U.S.: FDA

Mar. 7, 2018 at 11:32 a.m. ET
by Emma Court

Mylan shares bounce on plans for Botox copycat, 2018 drug launches

Mar. 4, 2018 at 12:37 p.m. ET
by Emma Court

Biogen, AbbVie to take multiple sclerosis drug off global market

Biogen Inc. and AbbVie Inc. said early Friday that the companies are voluntarily withdrawing their relapsing multiple sclerosis drug, Zinbryta, from global markets. Evaluating the drug's "complex and evolving benefit/risk profile... will not be possible going forward given the limited number of patients being treated," the companies said. The withdrawal is in patients' best interests, said Biogen Chief Medical Officer Alfred Sandrock. Zinbryta, which the companies said is generally used in patients who have tried two or more other multiple sclerosis medications unsuccessfully, is currently sold in the U.S., where it was approved in May 2016, along with Europe, Switzerland, Canada and Australia. Earlier this year, restrictions to minimize risk of serious liver injury with Zinbryta were adopted in Europe. The European Medicines Agency is also investigating reports of inflammatory encephalitis and meningioencephalitis, two kinds of brain inflammation typically caused by infection; those and other safety issues like liver toxicity, hypersensitivity reactions and inflammatory/immune toxicity have limited the drug's profitability "in the context of a number of better options for the disease," said RBC Capital Markets analyst Brian Abrahams. The decision to pull the drug was made by the companies and not because of any Food and Drug Administration action, according to a FDA spokesperson. The spokesperson also said that the FDA believes the drug will stay on the market while a plan is developed. Patients taking Zinbryta should speak with their doctors, and shouldn't stop taking the medication without consulting their doctors, the spokesperson said. Zinbryta has been the least profitable of Biogen's stable of multiple sclerosis drugs, bringing in just $12 million in sales in the fourth quarter, about $53 million in global revenue last year and about $8 million the prior year. AbbVie and Biogen "essentially split profits" on the therapy, according to Abrahams, and Zinbryta revenues aren't broken out in AbbVie's financial results, which list only key product revenues. Company shares initially declined in premarket trade but later rebounded. Biogen shares have dropped 10.8% over the last three months and AbbVie shares have surged 19%, compared with a 1.3% rise in the S&P 500 .

Mar. 2, 2018 at 1:54 p.m. ET
by Emma Court

AbbVie shares drop 1.9%

Mar. 2, 2018 at 8:34 a.m. ET
by Emma Court

Biogen shares drop 2.4% premarket

Mar. 2, 2018 at 8:34 a.m. ET
by Emma Court

Withdrawing the drug is in best interest of patients, said Biogen executive

Mar. 2, 2018 at 8:34 a.m. ET
by Emma Court

Biogen, AbbVie: Drug's benefit/risk profile difficult to evaluate because of small number of patients being treated

Mar. 2, 2018 at 8:34 a.m. ET
by Emma Court

Biogen, AbbVie shares drop after 'voluntary worldwide withdrawal' of relapsing multiple sclerosis drug

Mar. 2, 2018 at 8:33 a.m. ET
by Emma Court

AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug

AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial testing it in women with uterine fibroids. The therapy, elagolix, combined with low-dose hormone therapy reduced heavy menstrual bleeding in 68.5% of women, compared with 8.7% of women on the placebo. The phase 3 trial, ELARIS UF-I, is the first of two late-stage studies, and the Wednesday release was based on topline results from a six-month primary analysis. Uterine fibroids affect an estimated 7.5 million U.S. women, and consist of growths in the uterus that can cause heavy bleeding, pain and bladder problems. Other companies are also developing drugs in this area, includingMyovant , Allergan and the biotech ObsEva . AbbVie and Neurocrine's elagolix is also being developed for endometriosis with associated pain, and is being reviewed by the Food and Drug Administration for that indication. AbbVie shares have surged 24.6% over the last three months, and Neurocrine shares have surged 14%, compared with a 4.5% rise in the S&P 500 .

Feb. 21, 2018 at 8:34 a.m. ET
by Emma Court

Stocks to Watch: Facebook, Amazon, AbbVie, Accenture, Darden, Pandora, Conagra, Guess

Among the companies with shares expected to trade actively in Thursday's session are Facebook, Amazon, AbbVie, Accenture, Darden Restaurants and Pandora Media.

Mar. 22, 2018 at 9:29 a.m. ET
on The Wall Street Journal

How to Outrun Amazon

Target invests in the future, but at a cost.

Mar. 10, 2018 at 12:01 a.m. ET
on Barron's Online

More Prison Inmates Get Access to Hepatitis-C Drugs

More prisoners with hepatitis C are becoming eligible for treatment with effective but costly drugs like Harvoni and Sovaldi from Gilead Sciences Inc., as a result of lawsuits filed by inmates in Massachusetts and Florida.

Mar. 9, 2018 at 4:36 p.m. ET
on The Wall Street Journal

Biogen and Abbvie Take Multiple Sclerosis Drug Off Market

Drugmakers Biogen and AbbVie said they are pulling their new multiple-sclerosis treatment Zinbryta from all global markets after several European patients suffered serious inflammatory brain disorders.

Mar. 2, 2018 at 2:43 p.m. ET
on The Wall Street Journal

Stocks to Watch: Boeing, Apple, U.S. Steel, McDonald’s, Microsemi, Nordstrom, Gap, Biogen

Among the companies with shares expected to trade actively in Friday's session are Boeing, Apple, U.S. Steel, McDonald's, Microsemi and Nordstrom.

Mar. 2, 2018 at 9:25 a.m. ET
on The Wall Street Journal

Boom in Share Buybacks Renews Question of Who Wins From Tax Cuts

U.S. companies are buying back their shares at an aggressive pace, stirring debates in Washington and on Wall Street about how savings from corporate tax cuts are being used and who benefits most.

Mar. 1, 2018 at 11:32 p.m. ET
on The Wall Street Journal

Tax Cuts and Confidence Drive Surge of Hikes

Companies are raising dividends in a very bullish climate. These moves have predictive power, powering the trend over subsequent quarters.

Feb. 23, 2018 at 10:05 a.m. ET
on Barron's Online

Trial Tests FTC’s Power to Referee Drugmakers’ Fight Against Generics

A trial under way in federal court in Philadelphia is testing the power of U.S. competition regulators to crack down on drug makers’ alleged moves to thwart the sale of low-cost generics.

Feb. 20, 2018 at 8:00 a.m. ET
on The Wall Street Journal

Finding Safe Payouts as Interest Rates Rise

12 stocks with plenty of room to raise their dividends.

Feb. 16, 2018 at 10:29 a.m. ET
on Barron's Online

3 Biotechs That Could Benefit From an M&A Frenzy

Two veteran Janus Henderson health-care managers talk about innovation and takeover potential in a dynamic sector.

Feb. 13, 2018 at 10:04 a.m. ET
on Barron's Online

13 Mega Stocks With Rising Payout Estimates

Wall Street has boosted the dividend projections for these giants by at least 2% over the last six months.

Feb. 3, 2018 at 12:01 a.m. ET
on Barron's Online

Biotech Ready to Bust Out

On Monday, the Nasdaq Biotech Index jumped 3.1%, its biggest gain in six months, taking it to a new 52-week high.

Jan. 27, 2018 at 12:01 a.m. ET
on Barron's Online

AbbVie Gives More Juice to Drug Rally

Abbvie’s strong earnings and bullish hepatitis C outlook mean more big gains for investors across the drug sector.

Jan. 27, 2018 at 10:00 a.m. ET
on The Wall Street Journal

Charting the Market

A graphic look at selected stock activity for the week ended January 26, 2018. Included are Intel, Starbucks, and Mattel.

Jan. 27, 2018 at 12:01 a.m. ET
on Barron's Online

What Could Signal the End of This Rally?

Consumers aren’t just spending money on clothes, cars, and whatever else catches their eye—they’re also rushing into stocks. That could augur trouble.

Jan. 27, 2018 at 12:01 a.m. ET
on Barron's Online

AbbVie Says Tax Overhaul Will Slash 2018 Effective Tax Rate to 9%

AbbVie Inc. said Friday the new U.S. tax overhaul will slash its effective tax rate to 9% for 2018 and yield savings the drugmaker said it would use to return cash to shareholders and boost employee compensation.

Jan. 26, 2018 at 5:06 p.m. ET
on The Wall Street Journal

Stocks to Watch: VMWare, Intel, Starbucks, Tesla, Nike, Western Digital, Honeywell, Rockwell Collins

Among the companies with shares expected to trade actively in Friday's session are Dell Technologies, Intel, Starbucks, Tesla, Nike and Western Digital.

Jan. 26, 2018 at 9:26 a.m. ET
on The Wall Street Journal

The Strong Case for Health-Care Spinoffs

Spinoffs and asset sales may benefit shareholders more than chasing growth in a frenzied health-care deals market.

Jan. 25, 2018 at 5:30 a.m. ET
on The Wall Street Journal

The Perks of Overpricing

In ranking patent citations, three economists find more innovative research at firms with overvalued stocks.

Jan. 20, 2018 at 12:01 a.m. ET
on Barron's Online

Abby Joseph Cohen: Drilling for Oil and Making Gadgets

She likes Occidental Petroleum and Samsung

Jan. 20, 2018 at 12:01 a.m. ET
on Barron's Online

Other News
Press Releases

This Explains Why AbbVie Is Falling Today

Mar. 22, 2018 at 11:00 a.m. ET
on Motley Fool

How Gilead’s HCV Drugs Performed in 2017

In 4Q17, Gilead Sciences’ (GILD) Harvoni generated revenues of $644 million, which reflected a ~61% decline on a year-over-year (or YoY) basis and a 34% decline on a quarter-over-quarter basis.

Mar. 21, 2018 at 3:58 p.m. ET
on MarketRealist.com

Abbvie backs away from pursuing accelerated approval for Rova-T after disappointing mid-stage data in third-line lung cancer; shares down 7% premarket

Mar. 22, 2018 at 9:15 a.m. ET
on Seeking Alpha

How Did Gilead’s HIV Drugs Perform in 4Q17 and 2017?

In 4Q17, Gilead Sciences' (GILD) Truvada generated revenues of $797 million, which reflected an ~8% decline on a year-over-year (or YoY) basis and a 2% decline quarter-over-quarter.

Mar. 21, 2018 at 3:58 p.m. ET
on MarketRealist.com

Rituxan biosimilar captures 80% of British market

Mar. 22, 2018 at 7:18 a.m. ET
on Seeking Alpha

FDA OKs Sun Pharma's Ilumya for plaque psoriasis

Mar. 21, 2018 at 10:29 a.m. ET
on Seeking Alpha

Geron's Imetelstat Hits A Grand Slam, But The Rally Is Just Beginning

Mar. 21, 2018 at 5:25 a.m. ET
on Seeking Alpha

You Didn't Have To Let JNUG Get You Down

Mar. 21, 2018 at 3:04 a.m. ET
on Seeking Alpha

Biotechs Approaching New Waters

Mar. 20, 2018 at 12:01 p.m. ET
on Seeking Alpha

Protalix Should Be Looked At After Positive Ulcerative Colitis Data

Mar. 20, 2018 at 9:11 a.m. ET
on Seeking Alpha

3 Healthcare Stocks Hedge Funds Like the Most

Mar. 20, 2018 at 6:31 a.m. ET
on Motley Fool

Drug stocks in the red on as Trump mulls suing pharma firms over opioid crisis

Mar. 19, 2018 at 3:35 p.m. ET
on Seeking Alpha

J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit

J&J (JNJ) receives an offer for its LifeScan unit from private firm, Platinum Equity. It has time until Jun 15 to accept the offer, failing which it will expire.

Mar. 19, 2018 at 10:41 a.m. ET
on Zacks.com

Jefferies Adds Red-Hot Retail Stock to Franchise Picks List

Jefferies has made a big move by adding a top retail company to its well-respected Franchise Picks list of stocks to Buy.

Mar. 19, 2018 at 9:17 a.m. ET
on 247WallSt.com

Biotech Bio Series #2: Is Gilead Still A Growth Stock?

Mar. 19, 2018 at 10:04 a.m. ET
on Seeking Alpha

The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene

Mar. 19, 2018 at 8:34 a.m. ET
on Zacks.com

Why Multiple Sclerosis is a Promising but Risky Space?

Multiple Sclerosis (MS) is a promising space but risks continue to persist with the recent withdrawal of Zinbryta.

Mar. 16, 2018 at 11:12 a.m. ET
on Zacks.com

Pharma Stock Roundup: ABBV's Elagolix Meets Study Goal, MRK's Keytruda in Focus

Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.

Mar. 16, 2018 at 10:46 a.m. ET
on Zacks.com

5 Must-See Quotes From AbbVie's Management

Mar. 16, 2018 at 8:18 a.m. ET
on Motley Fool

3 Things In Biotech, March 15: AbbVie's Breakthrough, Bellicum Strikes Back, Sarepta's Guidance

Mar. 16, 2018 at 8:00 a.m. ET
on Seeking Alpha

AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer

Mar. 22, 2018 at 8:45 a.m. ET
on PR Newswire - PRF

AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma

Mar. 21, 2018 at 9:00 a.m. ET
on PR Newswire - PRF

Global Inhalation Anesthesia Market Opportunities 2018: Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group

Mar. 21, 2018 at 2:28 a.m. ET
on marketresearch.biz

Drugs for Rheumatoid Arthritis: Global Markets to 2022

Mar. 20, 2018 at 2:12 p.m. ET
on PR Newswire - PRF

Focal Segmental Glomerulosclerosis Market and Treatment Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017-2025

Mar. 14, 2018 at 10:29 a.m. ET
on PR Newswire - PRF

Inflammatory Bowel Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Mar. 14, 2018 at 9:48 a.m. ET
on PR Newswire - PRF

AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Mar. 13, 2018 at 8:00 a.m. ET
on PR Newswire - PRF

Today's Research Reports on Trending Tickers: AbbVie Inc. and Amgen Inc.

Mar. 9, 2018 at 8:31 a.m. ET
on ACCESSWIRE

Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and Eli Lilly

Mar. 8, 2018 at 6:20 a.m. ET
on PR Newswire - PRF

Leukemia Therapeutics Market Share 2018 Industry Analysis, Growth, and Forecast to 2022

Mar. 5, 2018 at 10:02 a.m. ET
on Financeswire

Julianne Hough Encourages Women to "Speak Up for Endo" during Endometriosis Awareness Month

Mar. 5, 2018 at 8:00 a.m. ET
on PR Newswire - PRF

The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a compound annual growth rate (CAGR) of 18.0% for the period of 2017-2022

The global market for non-opioid pain treatment totaled $9.9 billion in 2017 and is estimated to reach $22.6 billion by 2022, growing at a compound annual growth rate (CAGR) of 18.0% for the period of 2017-2022

Feb. 26, 2018 at 2:03 p.m. ET
on PR Newswire - PRF

AbbVie to Present at the Barclays Global Healthcare Conference

Feb. 26, 2018 at 8:00 a.m. ET
on PR Newswire - PRF

Immunotherapy Drugs Market 2018 Industry Analysis, Growth, and Forecast to 2022

Feb. 26, 2018 at 5:11 a.m. ET
on Financeswire

High Potency API and HPAPI Market 2018 Industry Analysis, Growth, and Forecast to 2022

Feb. 26, 2018 at 2:42 a.m. ET
on Financeswire

Wired News - Voyager Therapeutics Signs Global Collaboration Agreement with AbbVie to Develop New Treatments for Tau-Related Neuro-Degenerative Diseases

Feb. 22, 2018 at 1:44 p.m. ET
on ACCESSWIRE

AbbVie to Present at the Cowen and Company 38th Annual Health Care Conference

Feb. 22, 2018 at 8:00 a.m. ET
on PR Newswire - PRF

Leukemia Therapeutics Market 2018 is Expected To Be Worth US$ 12 Billion By 2022

Feb. 21, 2018 at 9:28 a.m. ET
on Financeswire

AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

Feb. 21, 2018 at 8:00 a.m. ET
on PR Newswire - PRF

Global Endometriosis Industry

Feb. 20, 2018 at 10:04 a.m. ET
on PR Newswire - PRF

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL. (See Full Profile)

Sell
Under
Hold
Over
Buy

Number of Ratings 23 Full Ratings

Height Casts 65% Odds That Congress Rolls Back Pharma Discounts

Mar. 7, 2018 at 11:31 a.m. ET
on Benzinga.com

Canaccord Slices Regeneron Price Target 32% On Eylea, Dupixent Challenges

Feb. 21, 2018 at 11:07 a.m. ET
on Benzinga.com

With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline

Feb. 7, 2018 at 2:37 p.m. ET
on Benzinga.com

Name	Chg %	Market Cap
Amgen Inc.	-1.93%	$130.99B
Neurocrine Biosciences Inc.	0.36%	$7.51B
Gilead Sciences Inc.	-1.24%	$100.2B
Biogen Inc.	-0.32%	$58.66B
AstraZeneca PLC ADR	-0.03%	$86.52B

Competitor Data Provided By

Dow	24,727.27	116.36	0.47%
S&P 500	2,716.94	4.02	0.15%
Nasdaq	7,364.30	20.06	0.27%
GlobalDow	3,090.98	2.12	0.07%
Gold	1,315.50	3.60	0.27%
Oil	63.42	1.36	2.19%

AbbVie Inc.

$ 97.79

Customize MarketWatch

No Items in Watchlist

No Saved Watchlists

Uh oh

No Recent Tickers